Rutgers Cancer Institute’s Post

The National Cancer Institute (NCI)'s ViPOR regimen, a non-chemotherapy treatment, is helping B-cell lymphoma patients achieve full remission. Dr. Christopher Melani joins our #HealthCast to explain the synergy of combining five therapies to shrink tumors effectively. Listen now to learn more about the upcoming phase of the study and the potential of precision medicine in cancer treatment: https://lnkd.in/dznzWd9T NCI Center for Cancer Research

Ryan Jacobs, the Director of Lymphoma at Levine Cancer Institute - Cleveland, presents in this MEDtalk an update on his research from the EHA 2023 meeting on AZD-0486, a novel CD19/CD3 T-cell engager used in treating relapsed refractory follicular lymphoma. The update includes patient responses and tolerability information, highlighting findings such as high overall response rates, complete remission rates, and low toxicity with the double step-up dosing method. 🔗Follow along as we cover EHA 2024: https://lnkd.in/d4be5h5W #EHA24 #Lymphoma

Myeloma Paper of the Day - Robert Z. Orlowski https://lnkd.in/gG-Besxb #oncodaily #oncology #cancer #MyelomaResearch #CARTtherapy #BCMA #Immunotherapy #MedicalScience #ResearchUpdate

Ryan Jacobs, the Director of Lymphoma at Levine Cancer Institute - Cleveland, presents in this MEDtalk an update on his research from the EHA 2023 meeting on AZD-0486, a novel CD19/CD3 T-cell engager used in treating relapsed refractory follicular lymphoma. The update includes patient responses and tolerability information, highlighting findings such as high overall response rates, complete remission rates, and low toxicity with the double step-up dosing method. 🔗Follow along as we cover EHA 2024: https://lnkd.in/dPW-ansy  #EHA24 #Lymphoma

Check out the link below to learn more about the work Sophie Kushman and I will be presenting at #ASCO2024

Scientists at NIAID and the National Cancer Institute (NCI) have prospectively identified distinguishing features and patterns in the tumors and lymph-node tissue of people with #FollicularLymphoma who relapsed within 24 months of initial treatment compared with those who did not. These findings could help clinicians predict early relapse among people with follicular lymphoma and inform treatment decisions. The scientists conducted the research in part with technology they created—an imaging system called IBEX—that enabled a fine-grained analysis of lymph-node cells in the context of their tissue microenvironment. The findings are published in the journal Cancer Cell. Read more: https://lnkd.in/e_A9h_PW More on IBEX: https://lnkd.in/eerHscxN #NIH

Ryan Jacobs, the Director of Lymphoma at LEVINE CANCER INSTITUTE - CLEVELAND, presents in this MEDtalk an update on his research from the EHA 2023 meeting on AZD-0486, a novel CD19/CD3 T-cell engager used in treating relapsed refractory follicular lymphoma. The update includes patient responses and tolerability information, highlighting findings such as high overall response rates, complete remission rates, and low toxicity with the double step-up dosing method. 🔗Follow along as we cover EHA 2024: https://lnkd.in/dGGgc_CW #EHA24 #Lymphoma

Molecular profiling has become an essential tool in cancer clinical management of cancer patients. It's required to have fluorescence in situ hybridization (FISH), immunohistochemistry (IHC), and next-generation sequencing (NGS) of DNA and/or RNA, which can uncover certain genetic mutations or molecular changes, that underlie and drive a patient’s tumor growth, metastasis, treatment resistance, and recurrence. In addition, most parmacogenetics with the highest level of evidence variants are related to somatic mustation associated with various of tumor types (required to be tested).

🎀 Despite billions spent on cancer research, significant gaps remain, particularly in protocols that prioritize the patient experience. Our partner, Courtney Shihabuddin, a breast cancer survivor and DIA 2024 Patient Partner, highlights that "most clinical research for breast cancer focuses on the postmenopausal population, yet young women and those with metastatic breast cancer are disproportionately affected and under-researched." She emphasizes, "Metastatic breast cancer is the only cancer that kills, and there’s just not enough research in these segments. We need more focus here." 📽️ Watch now: https://lnkd.in/eqCxxMkS Work with Courtney and the BJE team to develop patient-centric protocols that address these gaps and provide better outcomes for both patients and researchers. #CancerResearch #PatientAdvocacy #DIA2024 #BJEConsultants #ClinicalTrials #Clinicalresearch #PatientCenteredCare #HealthEquity #womeninmedicine #oncology

Researchers at VCU Massey Cancer Center have uncovered a promising path towards innovative treatments for colon cancer. Dr. Can Senkal and his team discovered that targeting a protein called Hsp27 can disrupt the energy supply crucial for tumour growth, offering new hope in the fight against this disease. This pivotal finding isn't just limited to colon cancer; it could revolutionise how we approach other solid tumours, including those in the lung, pancreas, and prostate. Keep an eye on this space for further developments, as this research holds great promise for advancing cancer treatment and offers new hope in the battle against this formidable disease. Read Full Article Here: https://bit.ly/475FxiN Follow us for Daily Stories in the Medical Space! #MasseyCancerCenter #CancerResearch #ColonCancer #Hsp27 #TargetedTherapy #CancerFight #InnovationInOncology #SolidTumorTreatment #HopeInResearch #HealthInnovation